111 related articles for article (PubMed ID: 6148474)
1. Recovery and inactivation of infectious retroviruses from factor VIII concentration.
Levy JA; Mitra G; Mozen MM
Lancet; 1984 Sep; 2(8405):722-3. PubMed ID: 6148474
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of retroviruses in biologicals manufactured for human use.
Hilfenhaus J; Gregersen JP; Müller H; Nowak T; Pranter W
Dev Biol Stand; 1991; 75():159-69. PubMed ID: 1794617
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates.
Heldebrant CM; Gomperts ED; Kasper CK; McDougal JS; Friedman AE; Hwang DS; Muchmore E; Jordan S; Miller R; Sergis-Davenport E
Transfusion; 1985; 25(6):510-5. PubMed ID: 3934800
[TBL] [Abstract][Full Text] [Related]
4. Safety of human blood products: inactivation of retroviruses by heat treatment at 60 degrees C.
Hilfenhaus J; Mauler R; Friis R; Bauer H
Proc Soc Exp Biol Med; 1985 Apr; 178(4):580-4. PubMed ID: 2984690
[TBL] [Abstract][Full Text] [Related]
5. Preliminary clinical experience: pharmacokinetics and tolerance of a double-virus-inactivated factor VIII preparation.
Martinowitz U
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S84-5. PubMed ID: 7495976
[TBL] [Abstract][Full Text] [Related]
6. Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. The Study Group of the Fondazione dell'Emofilia.
Mannucci PM; Zanetti AR; Colombo M; Chistolini A; De Biasi R; Musso R; Tamponi G
Thromb Haemost; 1990 Oct; 64(2):232-4. PubMed ID: 2176748
[TBL] [Abstract][Full Text] [Related]
7. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
8. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
9. [Anti-hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity].
Gutsalo AE; Varetskaia TV; Kozulina EP; Papaian LP
Ukr Biokhim Zh (1978); 1995; 67(1):3-13. PubMed ID: 8588250
[TBL] [Abstract][Full Text] [Related]
10. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
11. [Advances in hemophilia treatment: a hepatitis-safe factor VIII concentrate].
Heimburger N
Blut; 1982 Apr; 44(4):249-51. PubMed ID: 6805537
[No Abstract] [Full Text] [Related]
12. Validation of removal of human retroviruses.
Marcus-Sekura CJ
Dev Biol Stand; 1991; 75():133-43. PubMed ID: 1794615
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
Hilfenhaus J; Nowak T
Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
[TBL] [Abstract][Full Text] [Related]
14. Safety of pasteurised factor VIII (haemate HS).
Delvos V; Weidmann E; Hilfenhaus J; Mauler R
Lancet; 1988 Nov; 2(8620):1141-2. PubMed ID: 2903355
[No Abstract] [Full Text] [Related]
15. Reduction in risk of hepatitis transmission by heat-treatment of a human Factor VIII concentrate.
Hollinger FB; Dolana G; Thomas W; Gyorkey F
J Infect Dis; 1984 Aug; 150(2):250-62. PubMed ID: 6432922
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic properties and safety of recombinant factor VIII and factor IX.
Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
[TBL] [Abstract][Full Text] [Related]
17. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
18. Should hemophilia treaters switch to albumin-free recombinant factor VIII concentrates.
Meeks SL; Josephson CD
Curr Opin Hematol; 2006 Nov; 13(6):457-61. PubMed ID: 17053459
[TBL] [Abstract][Full Text] [Related]
19. B19 parvovirus withstands "super heating" in antihemophilic concentrates.
Morfini M; Azzi A; Mannucci PM
Thromb Haemost; 1996 Nov; 76(5):821. PubMed ID: 8950802
[No Abstract] [Full Text] [Related]
20. Virucidal treatment of clotting factor concentrates.
Mannucci PM; Colombo M
Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
[No Abstract] [Full Text] [Related]
[Next] [New Search]
